ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation facility in Boca Raton, Florida, and operates as an FDA-approved source plasma collector in the U.S. through its ADMA BioCenters subsidiary. This integrated, U.S.-based supply chain provides regulatory resilience and operational control in a specialized immunotherapy market.
Cyborg Score Rationale
FY 2025 preliminary revenue met guidance at $510-511 million with 12% year-over-year growth in Q3 2025 and 29% YoY Adjusted EBITDA growth. The company benefits from strong cash generation and is executing a $200 million capital return program, though concentrated product portfolio presents some risk.
Top Insights
FY 2025 preliminary revenue of $510-511M met guidance with consistent execution across quarters
March 3, 2026 ASR agreement with JPMorgan for $125M with 6.4M shares at $15.57/share closing price Feb 27, 2026—signals confidence in valuation
SG-001 hyperimmune globulin targeting S. pneumonia in pre-clinical development provides future pipeline optionality
Manufacturing improvements, capacity expansions, and new products driving margin growth with enhanced liquidity from refinancing underpinning strategic initiatives
Named Competitors
Intravenous Immunoglobulin (IVIG) Products — Global plasma-derived therapeutic manufacturer
Plasma-Derived Immunotherapies — Major multinational plasma fractionation company
Immune Globulin Products — European plasma-derived biopharmaceutical manufacturer
Recent Developments
(March 2026) $125M Accelerated Share Repurchase initiated with JPMorgan as part of $200M 2026 total repurchase program